AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials

AbbVie has revealed positive data from a post-hoc analysis of the Phase III Measure Up 1 and Measure Up 2 clinical trials of RINVOQ (upadacitinib) in treating moderate-to-severe atopic dermatitis (AD).